Last reviewed · How we verify
NCT07415551: CLEAR
Phase 2 Study of Lesigercept in Adult Patients With Chronic Spontaneous Urticaria Who Are Inadequately Controlled by H1-Antihistamines
Phase 2 trial testing Lesigercept in Allergic Diseases in 150 participants. Currently enrolling.
19 June 2027
Quick facts
| Lead sponsor | Yuhan Corporation |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 150 |
| Start date | 26 March 2026 |
| Primary completion | 19 June 2027 |
| Estimated completion | 24 July 2027 |
| Sites | 30 locations across China, Bulgaria, Poland, South Korea |
Drugs / interventions tested
- Lesigercept — full drug profile →
- Placebo
Conditions studied
- Allergic Diseases — all drugs for Allergic Diseases →
- Chronic Spontaneous Urticaria (CSU) — all drugs for Chronic Spontaneous Urticaria (CSU) →
Sponsor
Yuhan Corporation — full company profile →
Who can join
Adults 18 to 75, any sex, with Allergic Diseases or Chronic Spontaneous Urticaria (CSU). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate the efficacy and safety of lesigercept in approximately 150 participants with CSU. By enrolling participants with an inadequate response to H1-antihistamines, including those previously treated with omalizumab, this study is expected to provide evidence for the clinical utility of lesigercept and to further characterize its benefit-risk profile in the target participant population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07415551
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Allergic Diseases
Currently open trials in the same condition.
- NCT07148557 — A Study of Single Dose of LP-003 in Adolescent Subjects · Phase 1, PHASE2 · active not recruiting
- NCT06547372 — Dietary Intervention on Atopy · NA · recruiting
Other Yuhan Corporation trials
Trials by the same sponsor.
- NCT07470125 — Bioequivalence (BE) Study Between YHP2511 and YHP2511A in Healthy Volunteers · Phase 1 · not yet recruiting
- NCT07265167 — Bioequivalence Study Between YHP2406 and YHR2501 in Healthy Subjects · Phase 1 · completed
- NCT07111468 — Clinical Trial to Evaluate the Efficacy and Safety of YHP2401 Compared to YHR2402 and YHR2403 for Acute Bronchitis · Phase 3 · completed
- NCT06920719 — Bioequivalence Study betweenYHP2406 and YHR2501 in Healthy Subjects · Phase 1 · completed
- NCT06926387 — Bioequivalence Study betweenYHP2407 and YHR2502 in Healthy Subjects · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07415551 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yuhan Corporation
- Last refreshed: 15 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07415551.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing